Previous 10 | Next 10 |
Esperion Therapeutics, Inc. (ESPR) Q1 2022 Earnings Conference Call May 3, 2022 08:00 ET Company Participants Tiffany Aldrich - Senior Manager, Corporate Communications Sheldon Koenig - President and Chief Executive Officer Joanne Foody - Chief Medical Officer Eric Warren - Chief Commercial O...
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR) Q1 2022 Earnings Call May 03, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics (ESPR) Q1 2022 Earnings Call Transcript
Esperion (NASDAQ:ESPR) stock rose May 3 after Q1 results beat analysts' estimates. Q1 total revenues increased +136% Y/Y to ~$18.84M Y/Y. U.S. net product revenue of cholesterol lowering therapies Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid and ezetimibe) tablets...
Esperion Therapeutics press release (NASDAQ:ESPR): Q1 GAAP EPS of -$0.93 beats by $0.11. Revenue of $18.83M (+135.4% Y/Y) beats by $3.42M. For further details see: Esperion Therapeutics GAAP EPS of -$0.93 beats by $0.11, revenue of $18.83M beats by $3.42M
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $...
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.04 (+70.3% Y/Y) and the consensus Revenue Estimate is $15.41M (+92.6% Y/Y). Over the last 1 year, ESPR has beaten EPS estimates 25% of th...
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL ® , in the American Journal of Cardiology . The paper, ...
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10 th , 2022. ...
ANN ARBOR, Mich., April 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term LDL-cholesterol lowering in patients following a recent acute coronary syndrome (ACS) event. The ...
ANN ARBOR, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, May 3, 2022. Following the release, company management will host a webcast and co...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...